Par Drugs IPO description – Par Drugs is engaged in the development and manufacture of Active Pharma Ingredients (APIs) for the domestic market as well as for exports to international markets. APIs, also known as “bulk drugs” or “bulk actives” are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. The company currently produces a wide range of Antacid Molecules which are available in the market and are in great demand. For FY2019, domestic and international operations accounted for 89.51% and 10.49%, respectively, of its total sales.
The company owns and operates two manufacturing facilities at Bhavnagar and Ankleshwar in Gujarat. It currently has three Manufacturing Blocks at the Bhavnagar Facility for different products. The Bhavnagar facility is certified by food & drugs control administration. During the year 2011, it has added two manufacturing Block out of three at the Chitra, Bhavnagar facility. One is dedicated facility for the Main API and another one is for Fine Chemicals.
The company’s product portfolio presently comprises 12 APIs and 6 Fine Chemical which are marketed domestically and exported. It supplies its products to approximately 16 countries, including both direct and indirect exports. Its key customers include Essential Drugs Company Limited, Taurus chemicals (P) Limited, Pfizer Limited, United Phosphorus Limited (Samba Jammu Unit), Shiv Silica Private Limited.
Par Drugs promoters – Falgun Vallabhbhai Savani and Jignesh Vallabhbhai Savani
| Par Drugs – Upcoming IPO details | |
| Subscription Dates | 3 – 8 May 2019 |
| IPO Price band | INR51 per share |
| Fresh issue | 1,672,000 shares (INR8.53 crore) |
| Offer for sale | Nil |
| Total IPO size | 1,672,000 shares (INR8.53 crore) |
| Minimum bid (lot size) | 2,000 shares |
| Face Value | INR10 per share |
| Retail Allocation | 50% |
| Listing On | NSE Emerge SME platform |
Use of funds
- Working Capital Requirements – INR7.00 crore
- General Corporate Purposes – INR0.89 crore
- Issue Expenses – INR0.64 crore
| Par Drugs and Chemicals’ financial performance (in INR crore) | ||||||
| FY2017 | FY2018 | FY2019 | ||||
| Total revenue | 48.81 | 42.42 | 46.41 | |||
| Total expenses | 45.63 | 39.86 | 43.13 | |||
| Profit after tax | 1.85 | 1.50 | 2.42 | |||
Par Drugs and Chemicals Contact Details
Par Drugs and Chemicals Limited
302, Anmol Plaza
Waghawadi Road
Bhavnagar – 364001, Gujarat Phone: +91 278 2435400
Email: [email protected]
Website: www.pardrugs.com
Par Drugs IPO Subscription Details
| Day | Subscription (no. of times) |
| Day 1 | 0.20 |
| Day 2 | 0.67 |
| Day 3 | 1.29 |
| Day 4 | 5.35 |
Par Drugs Valuation (For FY2019)
Earnings Per Share (EPS): INR5.40
Price/Earnings (P/E) ratio: 9.44
Return on Net Worth (RONW): 8.31%
Net Asset Value (NAV): INR64.99 per share
Registrar of Par Drugs IPO
Link Intime India Private Limited
C-101, 1st Floor, 247 Park
Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai – 400 083 Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: [email protected]
Website: http://www.linkintime.co.in
Par Drugs IPO Allotment Status
Par Drugs IPO allotment status is now available on Link Intime’s website. Click on this link to get allotment status.
Listing performance of Par Drugs
IPO Opening Date: 3 May 2019
IPO Closing Date: 8 May 2019
Finalisation of Basis of Allotment: 13 May 2019
Initiation of refunds: 14 May 2019
Transfer of shares to demat accounts: 15 May 2019
Listing Date: 16 May 2019
Listing Price on NSE SME: INR52.9 per share (up 3.72% from IPO price)
Closing Price on NSE SME: INR50.45 per share (down 1.07% from IPO price)
